百特醫療 (BAX) 2018 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2018 Earnings Conference Call. (Operator Instructions)

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2018 年第三季財報電話會議。(接線員指示)

  • As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    提醒各位,本通話由百特錄音並受著作權保護。未經百特許可,不得錄製或轉播。如有任何異議,請於此時掛斷。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Thanks, Candace. Good morning, and welcome to our Third Quarter 2018 Earnings Conference Call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; Jay Saccaro, Baxter's Chief Financial Officer; and Brik Eyre, President, Americas.

    謝謝你,Candace。各位早安,歡迎參加我們 2018 年第三季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida;百特財務長 Jay Saccaro;以及美洲區總裁 Brik Eyre。

  • On the call this morning, we will be discussing Baxter's third quarter 2018 financial results along with our updated financial outlook for 2018. A supplemental presentation to complement this morning's discussion can be accessed on our website. This presentation, along with related non-GAAP reconciliations, can be accessed on Baxter's external website in the Investors section under Events and News.

    今天上午的電話會議中,我們將討論百特 2018 年第三季財務結果,以及我們更新後的 2018 年財務展望。可於我們網站取得補充簡報,以配合今天上午的討論。該簡報及相關的非 GAAP 調節表,可在百特對外網站「投資人」專區的「活動與新聞」項下取得。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contain forward-looking statements that involve risks and uncertainties.

    接下來,讓我以提醒各位開始我們的準備發言:本簡報(包括關於我們財務展望、新產品開發、業務開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。

  • And, of course, our actual results could differ materially from current expectations.

    當然,我們的實際結果可能與目前預期有重大差異。

  • Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially. In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance.

    請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以了解可能導致實際結果與預期有重大差異的因素之更多細節。此外,在今天的電話會議中,將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。

  • A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    今日所討論之非 GAAP 財務衡量指標與可比較 GAAP 財務衡量指標之調節表,已包含於我們今早發布並可於網站取得的財報新聞稿中。

  • On the call this morning, we will be discussing operational sales growth, which adjusts for the impact of foreign exchange, generic competition for cyclophosphamide in the U.S. and approximately 1 month of sales from the acquisition of Claris in July 2017 along with our acquisition of 2 surgical products from Mallinckrodt in the first quarter of 2018.

    今天上午的電話會議中,我們將討論營運銷售成長(operational sales growth),其已調整外匯影響、美國 cyclophosphamide 的學名藥競爭影響,以及 2017 年 7 月收購 Claris 所帶來約 1 個月的銷售額影響,並納入我們於 2018 年第一季自 Mallinckrodt 收購 2 項外科產品的影響。

  • Now I'd like to turn the call over to Joe. Joe?

    現在我想把電話交給 Joe。Joe?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Thank you, and good morning. I will begin with some comments and perspective on our third quarter results. Jay will then walk through the financials and guidance in greater detail, and we'll close with your questions. Brik Eyre, whom may you know from our May Investor Conference, will join us for the Q&A to provide additional insights on our U.S. performance.

    謝謝,各位早安。我將先就我們第三季結果提出一些評論與觀點。接著 Jay 會更詳細說明財務數字與財測指引,最後我們將進入問答。Brik Eyre(各位可能在我們 5 月投資人會議上認識他)將加入問答環節,提供我們美國業務表現的更多洞見。

  • Baxter reported solid third quarter with sales up 2% on a reported basis, 3% on a constant currency basis and 3% operationally. On the bottom line, adjusted earnings per share were $0.80, increasing 25% year-over-year.

    百特第三季表現穩健:以申報基礎(reported basis)計,銷售成長 2%;以固定匯率(constant currency)計,成長 3%;以營運口徑計,亦成長 3%。在獲利方面,調整後每股盈餘為 0.80 美元,年增 25%。

  • Our strong earnings growth demonstrates the continued power of our operational improvement initiatives, and we see more potential for these efforts moving forward. Drivers of growth in the quarter included the company's Renal Care, Pharmaceuticals, Advanced Surgery and Acute Therapies businesses; increased demand for Baxter's contract manufacturing services also contributed to the performance in the quarter. This strength helped offset declines in our Medication Delivery and Nutrition businesses.

    我們強勁的獲利成長展現了營運改善計畫持續發揮的力量,而我們也看到未來這些努力仍有更大潛力。本季成長動能來自公司腎臟照護、製藥、先進外科與急性治療等業務;對百特委託製造服務的需求增加,也對本季表現有所貢獻。這些強勢表現有助於抵銷我們藥物輸注(Medication Delivery)與營養(Nutrition)業務的下滑。

  • Growth in Renal Care was primarily driven by increased patient volumes for our peritoneal dialysis products globally. In the U.S., this contributed double-digit PD therapy growth. In Asia Pacific, we continued to see strong patient growth in China. And for the first time in years, we're experiencing positive patient growth in Japan following the launch of KAGUYA earlier this year.

    腎臟照護的成長主要由全球腹膜透析產品的病患量增加所帶動。在美國,這帶動 PD 治療呈現雙位數成長。在亞太地區,我們持續看到中國病患數強勁成長。而在日本,隨著今年稍早推出 KAGUYA,我們多年來首次出現病患數正成長。

  • In Pharmaceuticals, growth was driven by strength in the U.S., where we've experienced increased demand for our premixed injectables and extended our portfolio with the addition of Claris products. Claris, which we'll now refer to as Baxter a MetaBot, continues to deliver double-digit performance growth, in line with our expectations. Increased sales of anesthesia and critical care products also contributed to the results in the quarter. Advanced Surgery achieved double-digit growth, including the contribution of $14 million from sales of RECOTHROM and PREVELEAK.

    在製藥業務方面,成長由美國市場的強勁表現所帶動;我們的預混注射劑需求增加,並透過納入 Claris 產品擴充了產品組合。Claris(我們現在將其稱為 Baxter a MetaBot)持續交出符合我們預期的雙位數成長表現。麻醉與重症照護產品銷售增加,也對本季結果有所貢獻。先進外科達成雙位數成長,其中包含 RECOTHROM 與 PREVELEAK 銷售貢獻的 1,400 萬美元。

  • Acute Therapies also reported double-digit sales growth based on global strength across the portfolio. On Monday, this team initiated a worldwide launch of the leading-edge PrisMAX system beginning with 19 European countries. PrisMAX is our next-generation technology for CRRT, or continuous renal replacement therapy in organ support therapies. It offers ICU practitioners a broad range of advantages designed to make therapy simpler, safer, more accurate and more efficient. This is transformative innovation that builds on decades of Baxter market leadership in the acute care space. These strong results posted by this business was partially offset by performance in our U.S. Medication Delivery and Nutrition businesses, which were, frankly, disappointing.

    急性治療亦因產品組合在全球的強勁表現而呈現雙位數銷售成長。週一,該團隊已在全球啟動領先的 PrisMAX 系統上市,首波從 19 個歐洲國家開始。PrisMAX 是我們用於 CRRT(連續性腎臟替代治療,屬於器官支持治療)的下一代技術。它為加護病房(ICU)臨床人員提供多項優勢,旨在讓治療更簡單、更安全、更精準且更有效率。這是一項具變革性的創新,建立在百特數十年於急性照護領域的市場領導地位之上。然而,該業務的強勁成果部分被我們美國藥物輸注與營養業務的表現所抵銷;坦白說,那些表現令人失望。

  • I can assure you that steps are already being taken to address these issues. It starts with decisive action to put the right leadership in place, accountable for renewing the strategic momentum and forecast reliability that we and you expect. Overall, we remain on sound footing across a vast portfolio of products with market leadership positions.

    我可以向各位保證,我們已採取措施處理這些問題。首先是果斷行動,安排合適的領導團隊到位,並對重振策略動能與提升預測可靠性負起責任,這也是我們與各位所期待的。整體而言,我們在龐大的產品組合中仍維持穩健基礎,並在多個領域擁有市場領導地位。

  • To be certain, we are in a period of course correction in a few key areas, which we often occurs -- which rather, which often occurs from time to time in a dynamic market like ours. Let me drill down a few key areas starting with supply disruption due to Hurricane Maria.

    可以確定的是,我們在少數關鍵領域正處於調整修正的階段;在像我們這樣充滿動態變化的市場中,這種情況確實會不時發生——更正,是確實會不時發生。讓我從瑪麗亞颶風造成的供應中斷開始,深入說明幾個重點領域。

  • It has now become clear that market dynamics have fundamentally shifted in a few of our market segments in the aftermath of Hurricane Maria at least in the near to midterm. While we have resumed production at prehurricane levels, the gap in bringing supply back to market ultimately caused a longer-lasting ripple effect for several products line. End customer demand has now fully resumed to prior levels.

    如今已明確,在瑪麗亞颶風之後,至少在短至中期內,我們部分市場區隔的市場動態已發生根本性轉變。雖然我們已將產能恢復至颶風前水準,但將供應重新導回市場的缺口,最終對數條產品線造成更持久的連鎖效應。終端客戶需求目前已完全恢復至先前水準。

  • Specifically, with respect to small volumes -- rather with respect to small volume parenterals, which include our Mini-Bag and Mini-Bag Plus lines, we have seen impacts from protocol changes such as moving to IV push for administration of drugs as well as some moves to competitive products on supply constrained codes.

    具體而言,就小容量注射劑(small volume parenterals)而言——更正,就小容量注射劑而言(包含我們的 Mini-Bag 與 Mini-Bag Plus 產品線),我們已看到因流程/處置規範改變所帶來的影響,例如改採 IV push 方式給藥,以及在供應受限的品項代碼上,部分需求轉向競品。

  • While we expect to regain most of this business, we do anticipate it will take some time, particularly for the portion of the business that has moved to alternative practices for drug administration. We are continuing to reinforce the benefits of Mini-Bag Plus, emphasizing safety and reduced potential for medication errors.

    雖然我們預期可收復其中大部分業務,但我們也預期需要一些時間,特別是對於已轉向替代性給藥作法的那部分業務。我們將持續強化 Mini-Bag Plus 的效益訴求,強調安全性以及降低用藥錯誤的潛在風險。

  • We're also reinforcing the availability of supply with our customers. For select U.S. nutrition products, we've seen some market contraction as a result of hurricane-related supply constraints whether through providers delaying the start of parenteral nutrition and/or reducing dosage. We also experienced some shifts to outsourced nutrition compounding centers in competitive products. It is unlikely we'll regain all our lost sales here, particularly where we've seen market contraction at least in the near to midterm.

    我們也正與客戶一同強化供應可得性。就部分美國營養產品而言,我們看到因颶風相關的供應限制而導致市場出現一些萎縮,可能是因供應商延後開始腸外營養治療及/或降低劑量。在具競爭性的產品上,我們也經歷了一些轉向外包營養調配中心的情況。我們不太可能在此收回所有流失的銷售額,特別是在我們看到市場萎縮的情況下,至少在短期至中期內是如此。

  • We're in process of rebasing this business and expect to resume U.S. market growth of low single digits in the coming quarters. And while not directly related to the hurricane's impact on our production levels, the historic tight supply in the market for IV solutions has also impacted performance for the Medication Delivery business this year.

    我們正在對這項業務進行重置基準(rebasing),並預期在未來幾季恢復美國市場低個位數的成長。此外,雖然與颶風對我們產量的影響並無直接關聯,但靜脈輸液(IV solutions)市場長期供應吃緊也在今年影響了藥物輸送(Medication Delivery)業務的表現。

  • Sales of large-volume IV solutions spiked in the first 5 months of the year driven by increased purchased -- by increased purchases, given the protracted industry-wide supply challenges coupled with an intense flu season. Customers rushed to acquire any available IV solutions products. This resulted in growing inventory levels across our customer base.

    大容量靜脈輸液(large-volume IV solutions)的銷售在今年前5個月激增,主要由於在全產業供應挑戰持續、再加上嚴重流感季的情況下,採購量增加所致。客戶急於取得任何可供應的靜脈輸液產品。這使得我們客戶群的庫存水位上升。

  • Our forecast was built off this elevated run rate and didn't contemplate the level of inventory destocking we're currently experiencing as supply constraints have eased. In addition, the timing of adding incremental beds in nonacute customer has fallen short of our expectations. It's important to note that the end user demand for our LVPs is up approximately 2% year-to-date. We believe this is slightly ahead of the market, which we see as growing approximately 1%.

    我們的預測是以這種偏高的運行率為基礎建立的,並未考量到在供應限制緩解後,我們目前所經歷的庫存去化(destocking)程度。此外,非急性照護客戶新增床位的時點也未達到我們的預期。需要強調的是,我們的大容量輸液(LVPs)終端使用者需求年初至今約成長2%。我們認為這略高於市場,我們觀察市場約成長1%。

  • So ultimately, while our overall share has remained stable, the impact from the inventory destocking as well as the timing of bringing on new customers has clearly been slower than anticipated. As a result of these market dynamics, we are resetting expectation for these businesses in 2018. Going forward, our expectation is that the Medication Delivery and Nutrition business will grow in line with our long-term outlook.

    因此,最終而言,雖然我們的整體市占率維持穩定,但庫存去化的影響以及導入新客戶的時點,顯然都比預期更慢。基於這些市場動態,我們正在重設2018年對這些業務的預期。展望未來,我們預期藥物輸送與營養業務將與我們的長期展望一致地成長。

  • Taken together, these learnings will help support greater predictability and forecast alignment. We have a unique portfolio of life-sustaining products, and we've implemented some necessary changes that we believe will make our prospect both stronger now and over the long run.

    綜合而言,這些經驗將有助於提升可預測性並使預測更一致。我們擁有獨特的維生產品組合,並已實施一些必要的變革;我們相信這將使我們的前景在當下以及長期都更為強健。

  • In summary, our diversified portfolio, accelerating innovation, strong balance sheet and relentless focus on operational efficiency give us the confidence and flexibility to deliver on our long-term financial objectives.

    總結來說,我們多元化的產品組合、加速的創新、強健的資產負債表,以及對營運效率不懈的專注,使我們有信心並具備彈性來達成長期財務目標。

  • With that, I will turn it over to Jay.

    接下來我把時間交給Jay。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Thanks, Joe, and good morning, everyone. As Joe mentioned, although we've experienced challenging market dynamics in select businesses, our third quarter results reflect the benefit of our diversified portfolio as well as our ongoing commitment to accelerating bottom line growth.

    謝謝你,Joe,各位早安。如Joe所提,儘管我們在部分業務面臨具挑戰性的市場動態,我們第三季的結果反映了多元化產品組合的效益,以及我們持續致力於加速獲利成長的承諾。

  • I'll start by discussing our third quarter results before providing our updated financial outlook for 2018. Beginning with the third quarter, Global sales of $2.8 billion increased 2% on a reported basis, 3% at constant currency and 3% on an operational basis.

    我將先說明第三季業績,接著提供我們更新後的2018年財務展望。先從第三季開始,全球銷售額28億美元,按報告基礎成長2%,按固定匯率成長3%,按營運基礎成長3%。

  • On the bottom line, adjusted earnings increased 25% to $0.80 per diluted share. This exceeded our previous guidance of $0.72 to $0.74 per share driven by solid operational performance and ongoing benefit from our business transformation initiatives and a lower tax rate.

    在獲利方面,調整後盈餘成長25%,至每股稀釋後0.80美元。這高於我們先前每股0.72至0.74美元的指引,主要受惠於穩健的營運表現、業務轉型計畫的持續效益,以及較低的稅率。

  • Now I'll walk you through performance by our regions and Global Business Units. Note for this quarter, constant currency sales growth is equal to operational sales growth for all businesses with the exception of our Pharmaceuticals and Advanced Surgery business. For these businesses, we will provide operational growth.

    接下來我將帶各位檢視各區域與全球事業單位(Global Business Units)的表現。請注意,本季除製藥(Pharmaceuticals)與先進外科(Advanced Surgery)業務外,所有業務的固定匯率銷售成長等同於營運銷售成長。對於這些業務,我們將提供營運成長率。

  • Starting first with sales growth for our 3 regions. Sales in the Americas advanced 4% on a constant currency basis and 3% operationally. Sales in Europe, Middle East and Africa grew 4%, both constant currency and operationally. And finally, sales in our Asia Pacific region were flat on both a constant currency and operational basis.

    先從三大區域的銷售成長開始。美洲地區銷售按固定匯率成長4%,按營運基礎成長3%。歐洲、中東與非洲地區銷售成長4%,固定匯率與營運基礎皆為4%。最後,亞太地區銷售在固定匯率與營運基礎上皆持平。

  • As a reminder, in the third quarter of 2017, we recorded $25 million of sales in our international compounding business due to an early contract settlement with one of our Australian hospital pharmacy customers, which impacted growth in the Asia Pacific region by approximately 4%.

    提醒各位,2017年第三季,由於與澳洲某家醫院藥局客戶提前結算合約,我們在國際調配(international compounding)業務認列了2,500萬美元銷售額,這使亞太地區的成長率約受到4%的影響。

  • Moving on to performance by Global Business Units. Global sales for Renal Care were $910 million, advancing 3% on a constant currency basis. Performance was driven by mid-single-digit growth for PD therapies globally as well as low single-digit growth globally for our in-center HD business. Sales in Medication Delivery were $652 million, down 3% on a constant currency basis driven by the business dynamics that Joe walked through earlier. Pharmaceutical sales were $519 million, increasing 5% constant currency and 5% operationally. Sales growth in the quarter benefited from strength in our anesthesia business and increased demand for Baxter's injectable premixed drugs. Sales of U.S. cyclo were $40 million in the quarter, and global Claris sales were $38 million.

    接著看各全球事業單位的表現。腎臟照護(Renal Care)全球銷售額為9.10億美元,按固定匯率成長3%。表現主要由全球腹膜透析(PD)治療中個位數成長,以及全球院內血液透析(in-center HD)業務低個位數成長所帶動。藥物輸送(Medication Delivery)銷售額為6.52億美元,按固定匯率下滑3%,原因為Joe先前說明的業務動態。製藥銷售額為5.19億美元,按固定匯率成長5%,按營運基礎亦成長5%。本季銷售成長受惠於麻醉業務的強勁表現,以及市場對Baxter注射用預混藥品需求增加。本季美國cyclo銷售額為4,000萬美元,全球Claris銷售額為3,800萬美元。

  • Moving to Nutrition. Total sales were $218 million, down 2% on a constant currency basis. Solid growth in international markets was offset by lower sales in the U.S., which Joe commented on earlier. Sales in Advanced Surgery were $200 million, increasing 15% constant currency and 7% operationally.

    接著是營養(Nutrition)。總銷售額為2.18億美元,按固定匯率下滑2%。國際市場的穩健成長被美國較低的銷售所抵銷,Joe先前已提及。先進外科(Advanced Surgery)銷售額為2.00億美元,按固定匯率成長15%,按營運基礎成長7%。

  • As Joe mentioned, sales of RECOTHROM and PREVELEAK contributed approximately $14 million in the quarter. Sales in our Acute Therapies business were $122 million, representing growth of 10% on a constant currency basis, continuing the trajectory of delivering double-digit growth driven by increased global demand for Baxter's continuous renal replacement therapies.

    如Joe所提,RECOTHROM與PREVELEAK的銷售在本季合計貢獻約1,400萬美元。急性療法(Acute Therapies)業務銷售額為1.22億美元,按固定匯率成長10%,延續雙位數成長軌跡,主要由全球對Baxter連續性腎臟替代療法(continuous renal replacement therapies)的需求增加所帶動。

  • Finally, sales in our other category, which primarily includes our contract manufacturing services, were $146 million, an increase of 17% on a constant currency basis. Performance in the quarter was primarily driven by increased demand for our contract manufacturing services, specifically our cytotoxic contract manufacturing services as well as incremental production volumes for seasonal vaccines.

    最後是其他類別的銷售,主要包含我們的委託製造服務(contract manufacturing services),銷售額為1.46億美元,按固定匯率成長17%。本季表現主要由委託製造服務需求增加所帶動,特別是我們的細胞毒性(cytotoxic)委託製造服務,以及季節性疫苗的增量生產量。

  • Moving through the rest of the P&L. Our adjusted gross margin of 46.3% increased 100 basis points over the prior year, benefiting from favorable product mix and manufacturing efficiencies. Adjusted SG&A totaled $622 million, decreasing 1% on a reported basis and flat on a constant currency basis. We continue to see a positive contribution from our relentless focus on effective expense management and business transformation initiatives, which helped to offset the loss of approximately $10 million in transition service income from Shire and incremental expenses related to our recent acquisitions. Adjusted R&D spending in the quarter of $153 million increased 3% on a reported basis and 4% on a constant currency basis versus the prior year period as we continue to invest in high-impact programs to accelerate innovation at the company. Adjusted operating margin in the quarter was 18.3%, an increase of 170 basis points versus the prior year. Growth was driven by strong operational expansion as well as continued effective expense management.

    接著看損益表(P&L)的其餘項目。我們的調整後毛利率為46.3%,較去年同期提高100個基點,受惠於有利的產品組合與製造效率提升。調整後銷售、一般及行政費用(SG&A)合計6.22億美元,按報告基礎下降1%,按固定匯率持平。我們持續看到來自對有效費用管理與業務轉型計畫不懈專注的正面貢獻,這有助於抵銷來自Shire約1,000萬美元的過渡服務收入(transition service income)減少,以及與近期收購相關的新增費用。本季調整後研發(R&D)支出為1.53億美元,較去年同期按報告基礎成長3%,按固定匯率成長4%,因我們持續投資於高影響力計畫,以加速公司創新。本季調整後營業利益率為18.3%,較去年同期提高170個基點。成長主要由強勁的營運槓桿擴張,以及持續有效的費用管理所帶動。

  • Net interest expense was $11 million in the third quarter, reflecting higher levels of interest income due to rising interest rates. And other income totaled $32 million in the quarter, primarily reflecting a benefit from the recent changes we made to our U.S. pension plan along with foreign exchange gains on balance sheet positions.

    第三季淨利息費用為1,100萬美元,反映在利率上升帶動利息收入水準提高。此外,本季其他收入合計3,200萬美元,主要反映我們近期對美國退休金計畫所做變更帶來的利益,以及資產負債表部位的外匯收益。

  • The adjusted tax rate was 17.1% for the quarter, which includes a benefit of $9 million from stock compensation. This came in favorable to our expectations driven primarily by certain discrete items recorded in the quarter.

    本季調整後有效稅率為17.1%,其中包含來自股票酬勞的900萬美元稅務利益。此結果優於我們的預期,主要由本季認列的若干一次性(離散)項目所驅動。

  • And as previously mentioned, adjusted earnings of $0.80 per diluted share exceeded our guidance of $0.72 to $0.74 per share. During the quarter, we repurchased $247 million or 3.3 million shares of Baxter's stock. These repurchases were partially offset by option-related dilution in the quarter.

    另外,如先前提到的,調整後每股稀釋盈餘0.80美元,高於我們每股0.72至0.74美元的指引。本季我們回購了2.47億美元、約330萬股的百特股票。這些回購部分被本季與選擇權相關的稀釋所抵銷。

  • Before turning to 2018 outlook, I will briefly comment on our cash flow performance. In the first 3 quarters of 2018, we generated free cash flow of $873 million, with improvements in net income offset by higher inventory levels as we work to rebuild supply for select products to ensure adequate product availability.

    在談到2018年展望之前,我先簡要評論我們的現金流表現。2018年前三季,我們產生了8.73億美元的自由現金流;淨利改善的效益被較高的庫存水準所抵銷,因為我們正努力重建部分產品的供應,以確保充足的產品可得性。

  • Let me conclude my comments this morning by providing our guidance for the fourth quarter and full year 2018. Given the market dynamics we discussed for our U.S. Medication Delivery and Nutrition business, we've lowered our sales forecast for the year. Globally, we now expect 2018 full year sales to increase approximately 5% on a reported basis. We now expect growth of approximately 4% on a constant currency basis and approximately 3% on an operational basis.

    最後,讓我在今天上午的發言以提供第四季與2018全年指引作結。鑑於我們針對美國給藥與營養業務所討論的市場動態,我們下調了全年銷售預測。在全球範圍內,我們目前預期2018全年銷售額以報告基礎計算約成長5%。我們目前預期以固定匯率基礎約成長4%,以營運基礎約成長3%。

  • Moving to full year guidance by business. On a constant currency and operational basis except where otherwise noted, in Renal Care, we continue to expect growth of 3% to 4%. In Medication Delivery, we now expect sales to decline low single digits. We now expect our Pharmaceuticals business to increase high single digits at constant currency. This assumes 2018 U.S. cyclo sales of $160 million, above previous guidance of $130 million.

    接著看各業務的全年指引。除非另有說明,以下以固定匯率與營運基礎計算:在腎臟照護方面,我們仍預期成長3%至4%。在給藥方面,我們目前預期銷售將下滑低個位數百分比。我們目前預期製藥業務以固定匯率計算將成長高個位數百分比。此假設2018年美國cyclo銷售為1.6億美元,高於先前指引的1.3億美元。

  • We continue to expect full year Claris sales of approximately $145 million. Adjusting for cyclo and the first 7 months of Claris, we now expect operational sales to increase approximately 7%.

    我們仍預期Claris全年銷售約為1.45億美元。若就cyclo以及Claris前7個月進行調整,我們目前預期營運銷售約成長7%。

  • Moving to Nutrition. We now expect sales to decline low single digits. For our Advanced Surgery business, we now expect sales to increase approximately 10% on a constant currency basis. This includes a contribution of approximately $45 million related to the acquisition of RECOTHROM and PREVELEAK. Excluding the impact of these sales, operational growth is expected to be approximately 4%. For the Acute Therapies business, we now anticipate growth of 10% to 11%.

    接著看營養業務。我們目前預期銷售將下滑低個位數百分比。在先進外科業務方面,我們目前預期以固定匯率計算銷售約成長10%。其中包含與收購RECOTHROM與PREVELEAK相關、約4,500萬美元的貢獻。若排除這些銷售的影響,預期營運成長約為4%。在急性治療業務方面,我們目前預期成長10%至11%。

  • Finally, in our other business, we now expect growth of high single digits given increased demand for our contract manufacturing services.

    最後,在其他業務方面,鑑於我們委託製造服務需求增加,我們目前預期成長高個位數百分比。

  • Moving down the P&L. We now anticipate adjusted operating margin expansion of approximately 100 basis points. We expect net interest expense of approximately $45 million and other income of approximately $105 million for 2018.

    接著往下看損益表。我們目前預期調整後營業利益率擴張約100個基點。我們預期2018年淨利息費用約4,500萬美元,其他收入約1.05億美元。

  • For the year, we continue to expect an adjusted tax rate of approximately 17%. For full year 2018, we anticipate a diluted average share count between 545 million to 550 million shares. Based on these factors, we expect 2018 adjusted earnings, excluding special items, of $2.98 to $3 per diluted share.

    就全年而言,我們仍預期調整後有效稅率約為17%。2018全年,我們預期稀釋後加權平均股數介於5.45億至5.50億股。基於上述因素,我們預期2018年調整後盈餘(不含特殊項目)為每股稀釋2.98至3.00美元。

  • Finally, for the year, we now expect to generate operating cash flow of approximately $2.2 billion, with capital expenditures of approximately $700 million and free cash flow of approximately $1.5 billion, down slightly from our previous guidance due to higher inventory levels.

    最後,就全年而言,我們目前預期營業現金流約22億美元,資本支出約7億美元,自由現金流約15億美元;由於庫存水準較高,較先前指引略為下調。

  • Specific to the fourth quarter of 2018, we expect sales growth of approximately 1% on a reported basis and between 3% and 4% on both a constant currency and operational basis. And we expect adjusted earnings, excluding special items, of $0.71 to $0.73 per share.

    針對2018年第四季,我們預期以報告基礎計算銷售成長約1%,以固定匯率與營運基礎計算則介於3%至4%。我們也預期調整後盈餘(不含特殊項目)為每股0.71至0.73美元。

  • That concludes my comments. We can now open the call for Q&A. As a reminder, also on the call today is Brik Eyre, President, Americas, to join us during the Q&A. Candace?

    我的發言到此結束。我們現在可以開放問答。提醒各位,今天同一通電話會議中也有美洲區總裁Brik Eyre,將在問答環節與我們一同參與。Candace?

  • Operator

    Operator

  • (Operator Instructions) And our first question comes from Bob Hopkins of Bank of America Merrill Lynch.

    (接線員指示)我們的第一個問題來自美國銀行美林的Bob Hopkins。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • So, I guess, my concern looking at the last 2 quarters is that at least some of the issues that you're facing seem a bit structural given that you're experiencing share loss and a move to some alternative cheaper technology. So, I guess, my question is this, can you quantify for us or describe the degree to which you think you're losing share here and then help us understand how these issues could impact growth into 2019?

    所以,我想,我的擔憂是,從過去兩季來看,你們面臨的至少部分問題似乎有點結構性,因為你們正在經歷市占流失,以及市場轉向某些替代性的、更便宜的技術。因此,我的問題是:你們能否量化或描述一下你們認為在這裡流失市占的程度,並幫助我們理解這些問題可能如何影響2019年的成長?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Okay. Bob, I'm going to pick up half of the answer here, and I'm going to pass to Brik to get a little bit more color on the question on the share. First of all, there were shifts in the market because, us not having Mini-Bags and Mini-Bag Plus and amino acids, we actually were the ones teaching our customers how to use alternative methods. Some of them will come back, and we expect in 2019 to pick up a portion of that without a problem. The other ones will take a little longer for us to convert because those are medical practices. You have a significant amount of hospitals in the country, and we have large market share. I would say that we don't see the issues that we experienced in '18 by rebasing '18 to affect, tremendously, growth rates going forward. So as a matter of fact, I would say that the full year of 2018 results are the base for the LRP that we present in May, which runs from '18 to '23. So using the projected performance of 2018 we -- that we just shared with you, we are not revising our long-term guidance for total Baxter even the top or bottom lines. So there are structural issues. They take a little longer to resolve, but we have not lost any customers at this moment. And we may have lost some temporary share in accounts where some fluids are being substituted, which we expect from the mid- to long-term to recapture. I'd like to see if Brik would like to add anything to it.

    好的。Bob,我先回答其中一半,然後我會交給Brik,就市占的問題補充更多細節。首先,市場確實出現了轉變,因為我們沒有Mini-Bags、Mini-Bag Plus以及胺基酸產品時,實際上是我們在教導客戶如何使用替代方法。其中一些客戶會回來,我們預期在2019年可以毫無問題地收回其中一部分。其他的則需要更長時間才能轉換回來,因為那涉及醫療作業流程。全國有大量醫院,而我們擁有很高的市占。我會說,我們不認為把2018年作為基期(rebasing '18)後,2018年所經歷的問題會在未來對成長率造成很大的影響。事實上,我會說,2018全年結果是我們在5月提出的長期規劃(LRP)的基礎,該規劃涵蓋2018年至2023年。因此,基於我們剛與各位分享的2018年預估表現,我們不會修訂百特整體的長期指引,無論是營收端或獲利端。所以確實存在結構性問題。它們需要更長時間解決,但目前我們沒有失去任何客戶。而在一些以其他輸液替代的客戶帳戶中,我們可能暫時流失了一些市占;我們預期在中長期可重新奪回。我想看看Brik是否要補充任何內容。

  • Brik V. Eyre - Senior VP & President of Americas

    Brik V. Eyre - Senior VP & President of Americas

  • Yes. Thanks, Joe. Bob, let me talk about a couple of segments of the business. So first, our small-line parenterals. So these are 50-, 100-, 150-milliliter bags that are used to administer, infuse medication to patients. In that segment, when there were no products to be -- that our customers could find, about 25% of the doses that have historically been used or been administered through infusion, using our Mini-Bag and Mini-Bag Plus products, had to find other ways to administer those drugs. A portion of that went through a new practice, which is IV push. Now to be clear, IV push happens in every hospital every day across the country typically in OR drugs, et cetera. But in this particular case, when there was no product, specifically cephalosporins, penicillins, those anti-infectives, were moved to an IV push. This practice is the nurse literally takes a syringe and dilutes the drug into 5, 10 mls worth of diluent and then injects it into a port that is at the set at the hand, where there is access to the vein, and then they will do that over a period of time. There are some safety concerns, et cetera, that we are talking with our customers, but some customers have moved to IV push. And in so doing, they have to change their protocol. They change their protocol, they change their system, et cetera. So while we do believe we will get this back, it's taking a little bit more time than we had anticipated. Other customers went to competitive products. We actually feel very confident that we will get those products back, and we're working with our customers now to ensure that they understand that we have capacity, supply, et cetera. Now the other component of this is nutrition that was impacted from a -- the hurricane perspective. The nutrition business actually did contract. The market contracted. Whereas Joe mentioned in his -- in the opening comments, when customers didn't have product, they delayed start times, et cetera. So believe the overall nutrition market has contracted about 7%. We have also lost some share because we didn't have product, and we are working again with customers to get that share back. So while we don't think it's a long-term piece, certainly over the next few quarters, we anticipate seeing a ramp-up of bringing those products back to us. But anything that required a change in protocol will take a little bit more time.

    是的。謝謝,Joe。Bob,讓我談談業務的幾個區塊。首先,我們的小容量注射用輸液(small-line parenterals)。這些是 50、100、150 毫升的袋裝產品,用於向病人給藥、輸注藥物。在那個區塊,當市場上沒有產品——也就是我們的客戶找不到產品時——過去歷來透過輸注方式使用或施打的劑量中,大約有 25%(使用我們的 Mini-Bag 與 Mini-Bag Plus 產品)不得不改用其他方式來給藥。其中一部分轉向了一種新的作法,也就是 IV push(靜脈推注)。先說清楚,IV push 在全國各地的每家醫院每天都會發生,通常用於手術室(OR)用藥等等。但在這個特定情況下,當沒有產品時,特別是頭孢菌素、青黴素等抗感染藥,被改為以 IV push 方式給藥。這個作法是護理人員實際上拿一支注射器,把藥物稀釋到 5 或 10 毫升的稀釋液中,然後注射到設置在手部、可進入靜脈的輸液管路接口(port)中,並在一段時間內完成推注。我們正與客戶討論其中一些安全疑慮等等,但確實有些客戶已轉向 IV push。而這麼做,他們就必須更改作業流程。他們會改流程、改系統等等。因此,雖然我們相信會把這部分拿回來,但所需時間比我們原先預期的更長一些。其他客戶則轉向競品。我們其實非常有信心能把那些產品拿回來,並且正與客戶合作,確保他們了解我們具備產能、供應等等。另外一個受影響的部分是營養(nutrition),這是從颶風的角度所造成的影響。營養業務確實出現了萎縮。市場萎縮了。正如 Joe 在他的——開場評論中提到的,當客戶沒有產品時,他們會延後開始時間等等。因此我們認為整體營養市場大約萎縮了 7%。我們也因為沒有產品而流失了一些市占,現在再次與客戶合作把市占拿回來。所以雖然我們不認為這是長期問題,但在接下來幾個季度,我們預期會看到把這些產品帶回到我們這裡的爬坡回升。不過,任何需要更改流程的事情都會多花一點時間。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Just a very brief follow-up. Joe, is now the right time to be more aggressive with the balance sheet-related to buyback given your confidence that these things will be temporary?

    我再非常簡短追問一下。Joe,鑑於你有信心這些都只是暫時性的,現在是否是更積極運用資產負債表、進行庫藏股回購的合適時點?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • I would say that with the capacity that we have, and we're going to look at the sentiment of the investors, it's always a good time at this moment to look at some buybacks. But also we continue to use a significant amount of efforts inside Baxter in the M&A space. So we want to make sure that we have capacity to do all of the above, continue to increase our dividends annually and buy back shares and have plenty of capacity to go after M&A targets, which has a renewed and very focused effort at Baxter.

    我會說,以我們目前的產能,加上我們會觀察投資人的情緒,現在這個時點去評估一些回購,總是個好時機。但同時,我們在 Baxter 內部也持續在併購(M&A)領域投入大量心力。所以我們要確保有能力同時做到以上所有事情:持續每年提高股利、回購股票,並且保有充足的能力去追求併購標的;而這在 Baxter 已經是重新啟動且非常聚焦的努力方向。

  • Operator

    Operator

  • And our next question comes from Vijay Kumar of Evercore.

    下一個問題來自 Evercore 的 Vijay Kumar。

  • Vijay Muniyappa Kumar - MD

    Vijay Muniyappa Kumar - MD

  • And maybe just going back to Bob's question on some of the disruptions you guys have had. And this is a little unusual for you guys, where The Street's got used to stellar execution. So I just want to understand the dynamics, right? So you had -- I think, Joe, you mentioned LVPs. So if I'm understanding what happened on the LVP side is, customers prebought as in they built up inventories. One, how long does it take for them to work through those inventories? Should we still be expecting impacts in first half of '19? And then back to, I guess, Brik's sort of -- explanation on the push syringe impact. But I would think like, I mean, for 50 ml to 100 ml bags, someone pushing in using an IV push, that's a lot of inconvenience from a time -- use of time perspective in the hospital for the nurse. I'm just trying to think whether all of that comes back, or the assumptions around why some of that may not come back?

    我想回到 Bob 對你們近期一些供應中斷的提問。這對你們來說有點不尋常,因為華爾街(The Street)已經習慣你們一向出色的執行力。所以我想了解其中的動態,對吧?你們有——我想,Joe,你提到了 LVP(大容量輸液)。如果我理解 LVP 端發生的事情是,客戶提前採購,也就是他們建立了庫存。第一,通常需要多久他們才能消化掉那些庫存?我們是否仍應預期 2019 年上半年會受到影響?另外回到我想是 Brik 對推注注射器影響的——說明。但我會想,例如對 50 ml 到 100 ml 的袋裝產品,若改用 IV push 來推注,從醫院護理人員的時間使用角度看,這會非常不方便、很耗時。我只是想釐清,這些需求是否都會回來?或者你們對於為什麼其中一部分可能回不來的假設是什麼?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • So I'm going to have Brik answer 95% of your question. Just want to go back to the LVP. We now have a very good understanding of what happened in terms of stocking and destocking. As I said, we haven't lost a customer. But what we learned from this whole thing was that there was a pattern of purchases that were for many years in place, due to the product allocation that customers would buy whatever was available for them to buy because it was usually a little less than they would wish to purchase. We have created significant flexibility in the supply chain. And for the first time, we are in the market with no allocation, which creates flexibility for us, not to sell in U.S., but sell the product in other parts of Latin America, like we just did the other day in Mexico, extremely well-executed flexibility of supply chain. So we are going into a new era of LVPs where not only our plant in North Cove has done extremely well remediating and improving the output of the plant. So, at the same time, we resolved long-lasting quality issues. Things of the past have been resolved effectively. That plant is also now surpassing capacity plants because it's doing so well. We have capacity in Mexico, Ireland. So we now have the ability to really put the product to work. And this will be fundamentally important for us to resign customers that were -- we've signed in the past. When we talk about execution, we had an execution issue in the short term by having a team that did not understand what was happening with the difference between inventory in distributor and demand at the end of the day. It didn't change the dynamics. We did not see the signal, and we should have seen that and communicated more effectively. But to that end, we are relentless in execution. That's why we made significant changes in the U.S. team and have replaced people -- and plus we're replacing people who did not understand how we operate. I want to pass on to Brik to speak specifically about the push and how this business can come back in terms of market share as well.

    我會讓 Brik 回答你 95% 的問題。我只想先回到 LVP。我們現在對於補庫存與去庫存(stocking and destocking)所發生的情況有非常清楚的理解。如我所說,我們沒有失去任何客戶。但我們從整件事學到的是:由於產品配給(allocation),多年來客戶形成了一種採購模式——客戶會買任何他們能買到的量,因為通常可買到的量會比他們希望採購的量少一些。我們已在供應鏈中建立了顯著的彈性。而且是第一次,我們在市場上不再有配給,這為我們帶來彈性:不只是賣到美國,也能把產品賣到拉丁美洲其他地區,例如我們前幾天在墨西哥所做的那樣,供應鏈彈性運用得非常到位。因此,我們正進入 LVP 的新時代;不僅我們在 North Cove 的工廠在改善與提升產出方面做得非常好。同時,我們也解決了長期存在的品質問題。過去的問題已被有效解決。那座工廠現在也正在超越既有的產能水準,因為表現非常好。我們在墨西哥、愛爾蘭也有產能。所以我們現在真的有能力把產品充分投入市場。而這對我們重新簽回過去——我們曾經簽下的客戶,將具有根本性的重要性。談到執行力,我們短期確實有執行問題:當時的團隊不了解經銷商端的庫存與最終端需求之間的差異到底發生了什麼。這並沒有改變基本動態。我們沒有看到那個訊號,而我們本應看到並更有效地溝通。但即便如此,我們對執行是毫不鬆懈的。這也是為什麼我們在美國團隊做了重大調整並替換人員——此外我們也正在替換那些不了解我們運作方式的人。我想把時間交給 Brik,請他具體談談推注(push)以及這項業務在市占回升方面如何回來。

  • Brik V. Eyre - Senior VP & President of Americas

    Brik V. Eyre - Senior VP & President of Americas

  • So, Vijay, thank you. I want to just make sure I'm clear. In the package insert for administration of a ceph or a pen, for example, there's a couple of ways that they can do that. They can put into a Mini-Bag and infuse it over 30, 45 minutes of an infusion or -- and that would be like 100 ml. Or you can inject it through IV push with 5 to 10 mls of diluent. And so it's not -- they're not doing an IV push of 100 mls. It is 5 to 10. Now they will do that over 3- to 5-minute period of time. It will say in the package insert how long they should wait. The practical reality is studies have shown that a lot of times, they don't wait that long to push it and so there could be an overprescription or overdosing, and there could be a medication error. And that's one of the things we're talking to our customers about. So IV push, the issue really is they're comfortable with IV push for certain drugs, but those drugs that can be infused, cephs, pens, et cetera, really the best way to administer that drug is through Mini-Bags. And that's what we're talking to our customers about. Now I might take just a moment on LVPs to add just a little bit of color. This has been a business that's been highly successful for us for a number of years and has driven tremendous, tremendous growth. And the vast majority of that comes from new customer sign-ups. As you know, over the last 5 or 6 years, we've actually signed up to 3- to 5-year contracts, about 100,000 beds. So tremendous market shifts over the last 5, 6 years in our business from an LVP perspective. And that has been -- that coupled with an industry challenge in supply, our customers virtually purchased almost everything we could produce. In fact, these products have been on allocation. So we allocated a number of units that each customer could buy based on historical performance because we had to do that to make sure that we got product to every customer. As we discussed and as Joe just discussed, we brought more product from Latin America. We were able to increase the allocation to customers above their historical usage and ultimately, to remove that. As we did that, the demand for our products was tremendous in the first half of the year, particularly in the first quarter as customers were concerned and distributors as well were concerned about the hurricane disruption of the market in general as well as products that had just been on allocation for a long time exacerbated with a larger flu impact that we had in last quarters or last -- earlier this year. So there was tremendous, tremendous demand for our product. And then our U.S. team took that run rate on product that has always been able to -- whatever we manufactured, people purchased over the last 5 years because of allocation and used that for our forecast of the back half of the year. And they did so not realizing that distributors and customers purchase significantly over the end user demand the first half, most notably in the first quarter as I mentioned. Now the good news is, that those distributors have worked through that inventory caused a significant impact in the third quarter, but we believe that we are close to being back into equilibrium. We've been in contact with our distributors, our wholesalers. We know our end user demand. We get tracings from our distributors. So we are -- we've really improved our analytical capabilities, and certainly we will be at equilibrium over the next couple of months.

    所以,Vijay,謝謝你。我想先確認我理解正確。例如在頭孢類(ceph)或青黴素類(pen)的給藥說明書(package insert)中,給藥方式有幾種。他們可以把藥加入小輸液袋(Mini-Bag)中,於30、45分鐘進行輸注——那大概是100毫升。或者也可以用靜脈推注(IV push),搭配5到10毫升的稀釋液。因此並不是用IV push推100毫升。而是5到10毫升。現在他們會在3到5分鐘內完成推注。說明書會寫明應該等待多久。但實務上,研究顯示很多時候他們並不會等那麼久就推注,因此可能出現過度處方或過量給藥,也可能發生用藥錯誤。這也是我們正在與客戶溝通的重點之一。所以IV push的問題其實在於:對某些藥物他們很習慣用IV push,但對於那些可以輸注的藥物——頭孢類、青黴素類等等——真正最好的給藥方式是透過Mini-Bag。這就是我們正在與客戶討論的內容。另外我想花一點時間談談LVP,補充一些背景。這項業務多年來對我們非常成功,並帶動了非常、非常可觀的成長。其中絕大多數來自新客戶簽約。如你所知,過去5到6年,我們實際上簽下了3到5年期合約,合計約100,000張病床。因此從LVP的角度來看,過去5、6年我們的業務出現了巨大的市場轉移。而這一點——再加上產業供應面的挑戰——使得客戶幾乎把我們能生產的產品都買走了。事實上,這些產品一直處於配給(allocation)狀態。因此我們必須依據歷史表現,分配每位客戶可購買的數量,以確保每位客戶都能拿到產品。如我們先前討論、以及Joe剛剛提到的,我們從拉丁美洲引進了更多產品。我們得以把對客戶的配給量提高到高於其歷史使用量,並最終取消配給。在我們這麼做之後,上半年對我們產品的需求非常強勁,尤其第一季,因為客戶與經銷商都擔心颶風對整體市場的干擾;再加上這些產品長期配給,以及今年較早時期更嚴重的流感影響,使情況更為惡化。因此對我們產品的需求非常、非常強。接著我們美國團隊以這個產品的「運行速率」(run rate)作為下半年預測的基礎——過去5年因為配給的關係,我們生產多少就賣多少。但他們沒有意識到,經銷商與客戶在上半年(尤其如我所說的第一季)採購量顯著高於終端使用者需求。好消息是,這些經銷商已消化了該庫存,雖然對第三季造成了顯著影響,但我們相信目前已接近回到供需均衡。我們一直與經銷商、批發商保持聯繫。我們了解終端使用者需求。我們也會從經銷商取得出貨追蹤資料(tracings)。因此我們——確實提升了分析能力,而且我們肯定會在接下來幾個月回到均衡。

  • Vijay Muniyappa Kumar - MD

    Vijay Muniyappa Kumar - MD

  • That is extremely helpful, Brik. And maybe, Jay, just on the margin front, that was a stellar standout rate in terms of the positives. Irrespective of what the top line was, I mean, you guys have executed on margins, but as we -- it looks like maybe Q4, maybe there are some below-the-line items impacting. I'm having a little bit of a hard time getting to the low end of an EPS guide range. And when we look at '19, just qualitatively, should we be assuming some of these revenue headwinds persist, but on the margin front, the guide that you guys laid out at the Analyst Day, nothing changes on the margin front?

    這非常有幫助,Brik。另外也許,Jay,就毛利率(margin)方面來說,這在正面表現上非常突出。不論營收(top line)如何,你們在毛利率上確實執行得很好;但看起來可能在第四季(Q4)有一些線下項目(below-the-line items)在影響。我有點難把每股盈餘(EPS)指引區間的低端推算出來。而當我們看2019年('19)時,從定性角度來說,我們是否應該假設這些營收逆風仍會持續,但在毛利率方面,你們在分析師日(Analyst Day)提出的指引,毛利率端沒有任何改變?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Sure. Vijay, let me talk a little bit about Q4 and our expectations there. Because to your point, while in second half of the year, we were pleased to be able to confirm the overall guidance at the high end of the range, you point out very accurately that the Q4 implied guidance is down relative to what we previously shared. There's a few factors in play here, the largest of which is this issue that we've highlighted and discussed extensively about Medication Delivery and Nutrition. Overall, as we think about the impact in the fourth quarter relative to our prior expectations, that's about $0.06 of impact. Now offsetting that is savings initiatives that we have in place, roughly $0.01; cyclophosphamide impacts, approximately $0.03; and then there are a couple of financial adjustments, or financial items, I should say, related to foreign exchange and tax. We have taken -- we reduced our expectations with respect to FAS123R. So you do see a bit of a tax uptick. But in combination, foreign exchange and other financial items impact us roughly $0.04 in the quarter. So in combination, all of those items take us roughly down $0.05 midpoint to midpoint in the fourth quarter. As it relates to 2019, we'll stop short of giving guidance for that today. We do believe that there's real opportunity to recover, and I think Brik has discussed that extensively as has Joe. But as far as specific guidance for 2019, we'll stop short of that. We have reiterated confidence in the long-range plan that we shared, which shares through 2023 with also 2020 numbers.

    當然。Vijay,我先談談第四季以及我們對第四季的預期。因為如你所說,雖然在下半年我們很高興能在區間高端確認整體指引,但你也非常精準地指出,第四季的隱含指引相較我們先前分享的有所下調。這裡有幾個因素在起作用,其中最大的一項就是我們已重點提示並廣泛討論的「藥物輸送與營養」(Medication Delivery and Nutrition)問題。整體而言,若看第四季相對於我們先前預期的影響,約為0.06美元。抵銷項包括:我們已推動的節省措施,約0.01美元;環磷醯胺(cyclophosphamide)的影響,約0.03美元;另外還有幾項財務調整或財務項目,與外匯及稅務相關。我們已下調對FAS123R的預期。因此你會看到稅負略有上升。但合併來看,外匯與其他財務項目在本季對我們的影響約為0.04美元。綜合上述所有項目,第四季從中點到中點大約下調0.05美元。至於2019年,我們今天先不提供指引。我們確實認為有實質機會可以回復,我想Brik與Joe都已做了充分說明。但就2019年的具體指引而言,我們今天先不進一步提供。我們重申對先前分享的長期計畫的信心,該計畫涵蓋至2023年,並同時包含2020年的數字。

  • Operator

    Operator

  • And our next question comes from Robbie Marcus of JPMorgan.

    下一個問題來自摩根大通(JPMorgan)的Robbie Marcus。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • Great. I wanted to ask about some of the businesses that did well in the quarter, particularly Acute Therapies and Pharmaceuticals. These are ones where we've seen trends progressing positively each quarter. Can you help us understand Pharmaceuticals, what's driving that, how sustainable it is? And then in Acute Therapies, there were some new product launches recently. Can you help us understand the impact from those going forward?

    很好。我想問一些本季表現不錯的業務,特別是急性治療(Acute Therapies)與製藥(Pharmaceuticals)。這些業務的趨勢我們看到每一季都在正向進展。能否協助我們理解製藥業務:是什麼在驅動、可持續性如何?另外在急性治療方面,最近有一些新產品上市。能否協助我們理解這些新產品對未來的影響?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Can you repeat the second part of the question? I understood the Pharmaceuticals. I missed...

    你可以重複一下問題的第二部分嗎?我理解你說的製藥業務。我漏聽了……

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Acute Therapies in new product launches.

    急性治療(Acute Therapies)在新產品上市方面。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Acute Therapies, okay. Robbie, we had an extraordinary performance in the Pharmaceuticals business. Some of that is our capability of producing products that others can't and being there all the time. Cyclophosphamide is one of them despite the fact there's the new competitor that was authorized by the FDA to produce. We haven't seen the product coming out of this manufacturer yet. It's a very difficult product to make. We're not saying that we're the only ones who can because there's another competitor in the markets, and those has their product out there. But at the end of the day, we can make oncolytics and cytotoxics extremely well, one of the best in the market. We have BREVIBLOC that we do well and also TDS, which we source and be able to -- have the product for our customers. We don't see these products repeating the same performance all the time because as the nature of the business being when we can produce then people can't, people sometimes come back to the market. The BREVIBLOC is one that now has a couple of other manufacturers on the market, but we are always hedging our capabilities. So the performance of the Pharmaceuticals have been driven primarily by our ability to execute versus others who can't. I will give a little bit of a mid- to long-term view of Pharmaceuticals, which is our ability to continue to look into acquired molecules, which we've been doing. Second is our commitment to deliver on the LRP that Brik had presented at the Investor Day. We are still on track for all of that. Moving to the Acute Therapies, and I just want to say that we just launched PrisMAX, great product, launched in Europe. It's going to launch in the U.S. following. We are very excited. We're #1 in this therapy around the globe. You can see by the performance of this business and the performance of a competitor that just released earnings the other day, specifically yesterday, that we continue to be very successful in gaining share and also creating adoption for this technology. This just proves this is a structurally sound business, and we're very happy with the execution. I just also want to take the opportunity, you mentioned things that are going well, to underscore our launch of PD business and relaunch of our PD business in Japan with great success. And a 10% growth overall in China on all of our businesses combined. So we have some really good stuff happening. The unfortunate part is that we missed some of the market signals in the U.S. that created a headwind for us in Q3, will create in Q4 and we'll recover probably through '19 into '20. So we have some really good businesses within the company. They are really good cash generators and also we have a good and sound pipeline coming out on the company in '19 and '20.

    急性治療,好。Robbie,我們在製藥業務有非常出色的表現。其中一部分來自於我們能夠生產其他人做不出來的產品,並且能持續供應。環磷醯胺(Cyclophosphamide)就是其中之一,儘管有一家新的競爭對手已獲 FDA 授權可以生產。但我們還沒有看到該製造商的產品實際上市。這是一個非常難製造的產品。我們並不是說只有我們能做,因為市場上還有另一家競爭對手,而且他們的產品已經在市面上。但歸根結底,我們在腫瘤溶解藥(oncolytics)與細胞毒性藥物(cytotoxics)的製造上做得非常好,是市場上最好的之一。我們的 BREVIBLOC 表現也很好,另外還有 TDS,我們採購並能夠——為客戶提供產品。我們不認為這些產品會一直重複同樣的表現,因為這個業務的本質是:當我們能生產而別人不能時,別人有時候會回到市場。BREVIBLOC 現在市場上已有另外幾家製造商,但我們一直在對沖並強化我們的能力。因此,製藥業務的表現主要是由我們相較於無法執行的競爭對手所展現的執行能力所驅動。我也補充一下對製藥業務中長期的看法:第一是我們持續尋找可收購的分子(molecules),我們一直在做。第二是我們承諾交付 Brik 在投資人日所提出的 LRP(長期計畫)。我們目前仍按計畫推進。轉到急性治療,我想說我們剛在歐洲推出 PrisMAX,這是一個很棒的產品。接下來也會在美國上市。我們非常興奮。我們在全球這項治療領域排名第一。從這項業務的表現,以及某家競爭對手前幾天、特別是昨天剛公布的財報表現,你可以看到我們在提升市占以及推動這項技術的採用方面,持續非常成功。這也證明這是一個結構健全的業務,我們對執行成果非常滿意。另外也想藉此機會,你提到哪些事情進展順利,我想強調我們在日本成功推出並重新啟動 PD 業務(PD business)。以及我們在中國所有業務合計整體成長 10%。所以我們確實有一些非常好的進展。不幸的是,我們在美國錯過了一些市場訊號,這在第三季對我們造成逆風,第四季也會持續,並且我們可能會在 2019 年到 2020 年間逐步恢復。因此,公司內部有一些非常好的業務。它們是很好的現金產生器,而且我們在 2019 與 2020 年也會有良好且穩健的產品管線推出。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • Okay, great. And I know there've been a couple of questions on Medication Delivery. But just to look at it from a different angle, I haven't heard anything on in terms of how infusion systems have done in the quarter, year-to-date. Maybe how that's playing out with the system 8 launch. And then also can you comment on large volume pricing? I know you've said that volumes were up 2% year-to-date. How does the pricing situation look first half and then versus third quarter?

    好的,很棒。我知道關於藥物輸送(Medication Delivery)有幾個問題。但換個角度來看,我沒有聽到本季、以及年初至今輸注系統(infusion systems)的表現如何。也許可以談談這在 system 8 上市後的進展情況。另外也請你評論一下大容量(large volume)的定價。我知道你們說年初至今的量成長 2%。那麼上半年以及相較於第三季,定價情況看起來如何?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Robbie, just want to amend my answer on Pharmaceuticals that are premixes, which are replacements for -- we would sell premixes every day of the week in favor -- in detriment of Mini-Bag Plus, okay? Because premixes get a higher margin and they're up 18%, 18%. And they're reflected in Pharmaceuticals. They're not reflected in SVPs. Just want to highlight that because I missed that in my answer to you. So to the folks on the call, premixes has done extremely well. This is the GALAXY product, and those were ones that we told the customers to substitute for when we did not have Mini-Bag Plus available after the hurricane. So this is the positive side that we did not talk about. Let me pass on to Brik to answer the rest of your question.

    Robbie,我想補充修正我對製藥業務中預混液(premixes)的回答;預混液是用來替代——我們會在一週的每一天都更願意賣預混液,而不是——以犧牲 Mini-Bag Plus 為代價,好嗎?因為預混液的毛利更高,而且成長了 18%,18%。而且它們反映在製藥業務中。它們沒有反映在 SVPs 中。我只是想強調這點,因為我剛才回答你時漏掉了。所以對電話會議上的各位,預混液表現非常好。這是 GALAXY 產品,當颶風之後我們沒有 Mini-Bag Plus 可供應時,我們曾告訴客戶用這些來替代。所以這是我們剛才沒有談到的正面部分。我把其餘問題交給 Brik 來回答。

  • Brik V. Eyre - Senior VP & President of Americas

    Brik V. Eyre - Senior VP & President of Americas

  • So, Robbie, relative to pricing, with LVPs, nutrition, et cetera, the reality is these are products that are on longer-term contracts that have modest price increases built into those contracts. So pricing remains in line with our expectation across all of those product lines. Relative to infusion pumps, we continue to believe that we will pick up approximately 1% of market share this year in the United States with our SIGMA SPECTRUM pump. We have found that as more customers desire to have auto programming, one of the key features of our new pump that we've recently launched, our Spectrum IQ, which we sometimes refer to as version 9 and other integrated features that the selling cycle has lengthened a little bit. And so IT is now involved at a much higher level, at a hospital level -- or at a hospital, in each of our hospitals. And so we did reduce our pump number a little bit in the back half as products slip out into next year. But overall, we anticipate picking up the 1 percentage point as we had suggested earlier on with the new launch of SIGMA SPECTRUM.

    所以,Robbie,關於定價,LVP(大容量輸液)、營養等產品,實際情況是這些產品多半簽的是較長期合約,而合約中已內含溫和的價格調升。因此,這些產品線的定價整體仍符合我們的預期。至於輸注幫浦(infusion pumps),我們仍相信今年在美國,憑藉 SIGMA SPECTRUM 幫浦,我們將取得約 1% 的市占提升。我們發現,隨著更多客戶希望具備自動程式設定(auto programming)——這是我們近期推出的新幫浦 Spectrum IQ 的關鍵功能之一(我們有時稱之為第 9 版),以及其他整合功能——銷售週期拉長了一些。因此 IT 現在以更高層級參與,從醫院層級——或在我們每一家醫院中——參與度都高很多。所以在下半年,因為部分產品交付延後到明年,我們把幫浦出貨數量稍微下修了一點。但整體而言,隨著 SIGMA SPECTRUM 的新上市,我們預期仍能如先前所說,取得 1 個百分點的市占提升。

  • Operator

    Operator

  • And our next question comes from David Lewis of Morgan Stanley.

    下一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Maybe, Jay, just start with -- just start, Jay, with your question on free cash. So just free cash flow growth reversed a bit second quarter, third quarter. So I imagine there's been some supply chain reinvestment. Can you just sort of walk us through second quarter to third quarter? And as you think about sort of next year, do you think free cash flow gets back to that historical double-digit growth rate?

    Jay,或許先從——先從你關於自由現金的問題開始,Jay。所以自由現金流成長在第二季、第三季有些回落。我猜可能有一些供應鏈再投資。你能否帶我們梳理一下從第二季到第三季的變化?另外,當你展望明年時,你認為自由現金流是否會回到過去那種歷史性的雙位數成長率?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. Look, thinking about overall performance from a free cash flow, year-over-year, I think we're still talking about north of 20% growth, so very solid growth from 2017 to 2018. You'll recall earlier in the year, we raised free cash flow guidance. We had subsequently lowered it. And really what that has to do with is a couple of the factors that we discussed during this call. One is to the extent that you fall short on a sales forecast, I mean, it's very difficult to adjust your supply chain planning such that there is not an inventory build that takes place. The second thing is, we're very pleased with the performance coming out of our North Cove manufacturing facility, but that has been overproducing in terms of getting fully back up to speed ahead of our expectations, which is another factor contributing a bit to the inventory build. And then as we said earlier, when we look at year-over-year performance, we did make some strategic decisions to make select product inventory builds. So really, those are the 3 factors that we see. We do not see this as a structural issue. And frankly, once we kind of tighten up our forecast going into next year, this will be an opportunity for us to claw this back. So this year was -- if we think about the progression of free cash flow, we've gone from $300 million in 2015 to $1.5 billion in 2018. Inherently, when you see that kind of extraordinary growth, there will be some volatility and some puts and takes. We wanted to make sure we share the, obviously, the most updated thinking in terms of where we see this landing. But like I said, I don't believe this is a structural issue that we're faced with, and we will plan accordingly, as we look to next year.

    是的。你看,若從自由現金流的整體表現、以年對年來看,我認為我們仍在談超過 20% 的成長,因此 2017 到 2018 的成長非常穩健。你會記得在今年稍早,我們上調了自由現金流指引。之後我們又下調了它。而這真正關聯到的是我們在這通電話中討論的幾個因素。其一是,只要你的銷售預測未達標,我是說,你很難即時調整供應鏈規劃,避免發生庫存增加。第二點是,我們對北灣(North Cove)製造廠的表現非常滿意,但它在恢復到完全運轉方面超出我們預期、產量偏高,這也是促成庫存增加的另一個因素。再者,如同我們先前所說,當我們看年對年表現時,我們確實做出一些策略性決策,針對特定產品進行庫存建立。所以,基本上我們看到的就是這 3 個因素。我們不認為這是結構性問題。坦白說,一旦我們在進入明年時把預測收緊一些,這將會是我們把它追回來的機會。因此今年——如果我們思考自由現金流的演進,我們已從 2015 年的 3 億美元成長到 2018 年的 15 億美元。本質上,當你看到如此非凡的成長時,會出現一些波動以及一些利弊消長。我們希望確保與大家分享我們最新的想法,也就是我們認為最終會落在哪裡。但如我所說,我不相信這是我們面臨的結構性問題;我們會在展望明年時相應規劃。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • And just maybe 2 quick follow-ups. The first is for Joe or for Brik. We haven't heard a lot about the SVP manufacturing dynamics in Puerto Rico. How do they trend here in the third quarter, and what's the pathway to approval? Then, Jay -- sorry, just for the fourth quarter assumptions. We have 2 different dynamics, inventory and some of these customer changing dynamics. Inventory is you could look at tracing data and get relatively comfortable. Just basically trying to ask as it relates to customer recapture rates, how risk-adjusted are these fourth quarter numbers? And I'll jump back in queue.

    再補充兩個很快的追問。第一個是給 Joe 或 Brik。我們沒有聽到太多關於波多黎各 SVP 製造端的動態。第三季的趨勢如何?以及取得核准的路徑是什麼?然後,Jay——抱歉,關於第四季的假設。我們有兩個不同的動態:庫存,以及部分客戶變動的動態。庫存方面,你可以看追蹤資料並相對放心。我主要想問的是,就客戶回收率而言,這些第四季數字做了多少風險調整?我會回到隊列中。

  • Brik V. Eyre - Senior VP & President of Americas

    Brik V. Eyre - Senior VP & President of Americas

  • So let me first talk a little bit about SVPs, David. Our production level is back to where we want, need it to be, et cetera. We were able to put Mini-Bags back in the channel kind of mid-July, so midsummer. And we're starting to see an impact of having that back in the channel, which is a good thing as customers can buy from their primary distributors. Mini-Bag Plus just went back into the channel in September. We are healthy on most codes of Mini-Bag Plus. We've got 1 or 2 codes that we're still getting healthy on, but the vast majority of our business, we're very healthy now from a inventory perspective. And we are working, again, diligently with our customers relative to ensure that they have confidence in our ability to supply.

    David,我先談一下 SVP。我們的產量已回到我們希望、也需要的水準,等等。我們在 7 月中旬左右、也就是仲夏時,已讓 Mini-Bags 重新回到通路。我們開始看到它回到通路所帶來的影響,這是好事,因為客戶可以從其主要經銷商採購。Mini-Bag Plus 則是在 9 月才剛回到通路。我們在 Mini-Bag Plus 的大多數品項(codes)上供應狀況良好。仍有 1 到 2 個品項我們還在把供應拉回健康水準,但就我們絕大多數業務而言,從庫存角度來看現在已非常健康。而且我們也再次持續勤勉地與客戶合作,以確保他們對我們供應能力有信心。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • And then, David, from a fourth quarter financial forecast, we've spent a lot of time with a bonds up build up trying to be appropriately conservative as we look across the portfolio, and that includes LVPs. That includes SVP recapture and so on. And so I think we've got the right number as we look to Q4 in the guidance that we shared.

    另外,David,就第四季的財務預測而言,我們花了很多時間自下而上(bottoms up)建立模型,力求在檢視整個產品組合時保持適度保守,而這也包含 LVP。也包含 SVP 的回收,以及其他。因此,我認為就我們在指引中分享的內容來看,第四季(Q4)的數字是合適的。

  • Brik V. Eyre - Senior VP & President of Americas

    Brik V. Eyre - Senior VP & President of Americas

  • The only other thing I might add, David, is we have launched a new product which is sourced out of Castlebar, which is a single-pack Mini-Bag Plus product, which we're really excited about. From an operational efficiency perspective in the hospital, it's been very, very well received. And so this continues to diversify our risk as we have other sites manufacturing this Mini-Bag Plus product that is such a great product for us.

    David,我唯一想補充的是,我們已推出一項新產品,來源於 Castlebar,這是一款單包裝(single-pack)的 Mini-Bag Plus 產品,我們對此非常興奮。從醫院端的營運效率角度來看,它獲得非常、非常好的回饋。因此,隨著我們有其他廠址也在生產這款對我們而言非常出色的 Mini-Bag Plus 產品,這也持續分散了我們的風險。

  • Operator

    Operator

  • And our next question comes from Larry Biegelsen of Wells Fargo.

    下一個問題來自富國銀行(Wells Fargo)的 Larry Biegelsen。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • One on the P&L, one on capital deployment. So, Jay, in the past, you've been very helpful in pointing out kind of headwinds in the subsequent year, and you guys have been very good at being able to overcome those headwinds on the P&L. So for 2019, you have currency, cyclo, BREVIBLOC maybe on other income and tax potentially as headwinds. And in the aggregate, by our math, it could reduce 2019 EPS by about $0.40. So can you walk us through some of the P&L headwinds next year and help us understand if you can still grow EPS at a double-digit reported rate in 2019? And I had one follow-up.

    一個關於損益表(P&L),一個關於資本配置。Jay,過去你很常、也很有幫助地指出次年可能面臨的逆風,而你們也一直很擅長在損益表上克服這些逆風。所以對 2019 年而言,你們可能面臨匯率、cyclo、BREVIBLOC 可能在其他收入,以及稅務等方面的逆風。整體而言,按我們的計算,這可能使 2019 年 EPS 減少約 0.40 美元。你能否帶我們梳理一下明年損益表上的一些逆風,並幫助我們理解你們是否仍能在 2019 年以雙位數的「報告口徑」成長 EPS?我還有一個追問。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes, sure. Larry, stay tuned. Come join us on, I think, January 31 or February 1 for guidance for 2019. At this stage, I think it's premature. What we've said is we've shared financial guideposts for 2020 and 2023. There are numerous puts and takes, of which we've confirmed and feel confident in. There are numerous puts and takes as we look at any given year, I mean, our objective is to do as well as we possibly can do in any given year. And so certainly things like new product launches are things that we'll highlight as we come to our earnings call at the beginning of next year. But like I say, it's too premature to give 2019 guidance at this point.

    好的,當然。Larry,敬請期待。歡迎在 1 月 31 日或 2 月 1 日加入我們,屆時我們會提供 2019 年指引。在這個階段,我認為現在談還為時過早。我們已經說過,我們分享了 2020 年與 2023 年的財務路標(guideposts)。其中有許多利弊消長,我們已確認並且有信心。每一年在檢視時都會有許多利弊消長;我的意思是,我們的目標是在任何一年都盡可能做到最好。因此,像新產品上市這類事項,我們會在明年年初的財報電話會議上重點說明。但如我所說,現在給出 2019 年指引還太早。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • Understood. And Joe, regarding M&A at our health care conference, Jay, not to get you in trouble, but you said Baxter is agnostic to deal size, which surprised me a little bit. So Joe, I thought you had a strong preference for smaller deals because it was hard to get a good ROIC from larger deals. So my question is, has anything changed?

    了解。Joe,關於併購(M&A),在我們的醫療保健研討會上,Jay——不是要讓你為難——但你說 Baxter 對交易規模並不偏好(agnostic),這讓我有點意外。所以 Joe,我原本以為你更偏好小型交易,因為大型交易較難取得良好的投入資本報酬率(ROIC)。所以我的問題是,有什麼改變了嗎?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Thank you. Trying to figure out if Jay and I are on the same page, and we are actually. Jay called me right before he said this and asked, "can I say that." And I authorized him to say that without [Bernie] present. We are looking at any opportunity that we have either adjacent to the core or completely outside of the core in terms of another leg to the stool. And why do we take the constraint of size? Because that creates an issue in selecting targets, not necessarily that we will execute on that but not -- but being agnostic of size. What Jay meant to say was that we have -- we are looking at every opportunity that is -- that will get us what we need to do, which is to refresh the portfolio of Baxter, to create momentum on the gross margin line, augment growth on the top line and be accretive to the bottom line. We're doing this. And by taking the size from the restriction, we can see better what's available to us. But let me also put a commentary that was implied in Jay's response to your question during your conference, that is, we will push the boundaries of our debt ratio to the limit of investment grade, but not -- or below that. So that creates a size limitation of what we can do, okay? Secondly, I have to say to you that what Baxter has done in terms of its business transformation and what we're able to bring to the company when I first started about -- exactly 3 years ago yesterday, we had 9% of operating income, and now we are above 18% of operating income. That transformation of a company is difficult to achieve. But once you know and learn how to do it, it is paramount upon the acquisition. So if you think about when we talk about sizes and how we do it, it's not about integration per se, but it's our ability also to go in with that mentality, with that trademark and get the savings out of the target independently if the synergies are all in terms of connecting systems and doing the stuff that more traditionally people think about. I'm coming from a different angle that said that is doable, but the first thing we'll do, we'll put a business transformational office identical to what we have in Baxter at that company. And we're going to remove the cost and the fat that companies usually have in the medical technology and generics, pharmaceutical business. So it's a long answer to you to say that we are looking at multiple size deals. We're looking for in also adjacencies and outside of our space within the health care, but also we have the ability to really be a cost-driven organization, that can extract value from a target even if it's not core or highly synergistic to us.

    謝謝。我想確認 Jay 和我是否想法一致,而事實上我們確實一致。Jay 在他說這段話之前就打電話給我,問我「我可以這樣說嗎?」我也授權他在沒有 [Bernie] 在場的情況下這麼說。我們正在評估任何機會:不論是與核心業務相鄰,或是完全在核心之外,作為我們「凳子上的另一條腿」。那為什麼要加上規模的限制?因為那會在挑選標的時造成問題;並不是說我們一定會照那樣執行,但——而是我們希望對規模保持中立。Jay 想表達的是:我們——我們正在看所有能讓我們達成所需目標的機會,也就是更新 Baxter 的投資組合、在毛利率線上創造動能、強化營收端的成長,並且對淨利端具增益(accretive)。我們正在做這件事。把規模從限制中拿掉,我們就能更清楚看到有哪些選項。但我也補充一點:在你們會議上,Jay 回答你問題時其實隱含了一個評論,也就是我們會把負債比率的邊界推到投資級的極限,但不會——或低於那個水準。所以這也會形成我們能做的事情在規模上的限制,好嗎?第二,我必須跟你說,Baxter 在業務轉型上所做的,以及我大約——正好在昨天滿 3 年前剛開始時我們能帶給公司的改變:當時我們的營業利益率是 9%,現在已經超過 18%。要完成這樣的公司轉型是很難的。但一旦你知道並學會怎麼做,這在併購上就至關重要。所以當你想到我們談規模以及我們怎麼做時,重點不在整合本身,而在於我們也有能力帶著那種心態、那套方法論去做,即使協同效益只是連接系統、做那些更傳統上大家所想的事情,我們仍能獨立地從標的中把節省(savings)挖出來。我從不同角度來看:那當然做得到,但我們第一件事會是在那家公司設立一個與 Baxter 現有完全相同的業務轉型辦公室。我們會移除醫療科技與學名藥、製藥業務中公司通常存在的成本與冗脂。所以我用比較長的回答是想說:我們正在看多種不同規模的交易。我們也在尋找與我們相鄰的領域,以及在醫療保健範疇內但在我們既有領域之外的機會;同時我們也確實有能力成為一個以成本驅動的組織,即使標的不是核心、或與我們高度協同,我們仍能從中提取價值。

  • Operator

    Operator

  • And our next question comes from Larry Keusch of Raymond James.

    下一個問題來自 Raymond James 的 Larry Keusch。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Yes. Just wanted to -- we've already spent a lot of time on LVPs and SVPs, but wanted to come back to nutrition and just get some thoughts as it relates to sort of the protocols changing in terms of delayed starts for nutritional products. How do you influence that to kind of go back to where it was? Because, I guess, my concern is that could become a bit more permanent.

    是的。我想——我們已經在 LVP 和 SVP 上花了很多時間,但我想回到營養業務,請你談談關於營養產品在「延後開始」方面的流程(protocols)變更。你們要如何影響它,讓它回到原本的做法?因為我想,我的擔憂是這可能會變得更為永久化。

  • Brik V. Eyre - Senior VP & President of Americas

    Brik V. Eyre - Senior VP & President of Americas

  • So, Larry, let me take that if I can. Certainly, it's more problematic when protocols change. But ASPEN, the American Society for Parenteral and Enteral Nutrition, wrote some guidelines to help people when they were in conservation mode. There are guidelines for feeding. And while these patients are typically really, really sick, they don't have gut function. That is why they're on parenteral nutrition. So it's very difficult to be able to track specifically what the clinical outcome is to -- there are so many different inputs. But if you take a step back, we do know there's good data that would suggest that outcomes are better when a patient is nourished appropriately and effectively. So we are working with all of the societies now that there's an appropriate supply to see if we can help customers go back to feeding protocols that have been established by ASPEN here in the U.S., by ESPEN, which is in Europe, to help make sure that patients are fed appropriately. We'll continue to work with those societies, continue to work with our customers. But as you mentioned, when a protocol changes in the hospital, it just takes a little bit more time to get it back. We're working very closely with our customers, and they do recognize the importance of feeding. And we just have to make sure that they're confident in our supply chain and the supply chain to the market in total. And to your point or just from a framing perspective, about 7% of the market contracted, and we will be working over the next several quarters to bring that back.

    Larry,如果可以的話我來回答。當流程改變時,確實會更棘手。不過 ASPEN(美國靜脈與腸道營養學會)曾撰寫一些指引,協助大家在供應保全(conservation)模式下應對。那裡有關於餵養(feeding)的指引。而這些病人通常病得非常、非常重,他們沒有腸胃功能。這也是他們需要接受靜脈營養(parenteral nutrition)的原因。因此要精準追蹤臨床結果其實很困難——影響因素太多。但如果退一步看,我們確實知道有很好的數據顯示:當病人得到適當且有效的營養時,預後會更好。所以現在供應已經較為充足,我們正與各個學會合作,看看能否協助客戶回到在美國由 ASPEN、在歐洲由 ESPEN 所建立的餵養流程,以確保病人得到適當的營養。我們會持續與這些學會合作,也會持續與客戶合作。但如你所提到的,醫院一旦更改流程,要再改回來就需要多一點時間。我們正非常密切地與客戶合作,他們也認同餵養的重要性。我們必須確保他們對我們的供應鏈,以及整體市場的供應鏈都有信心。就你的觀點、或從框架來看,市場大約收縮了 7%,我們會在接下來幾個季度努力把它拉回來。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Okay. Perfect. And then 2 other perhaps quick ones. I think, Joe, you may have mentioned in your prepared comments about some management changes following some of the forecasting missteps, if you will, relative to the business. So, again, I want to make sure I heard that and kind of what the plans are there. And then for Jay, just on the gross margin expansion year-over-year, which was clearly impressive, just trying to understand the components that drove that expansion, if there any onetimers there.

    好的。很好。另外還有兩個可能很快的問題。Joe,我記得你在事先準備的發言中提到,因為業務在預測上出現一些失誤(如果這樣說的話),所以做了一些管理層變動。我想再次確認我有沒有聽對,以及你們接下來的計畫是什麼。另外問 Jay,關於毛利率年對年擴張,這顯然很亮眼;我想了解推動這個擴張的組成因素,以及其中是否有任何一次性因素(onetimers)。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • We always look at execution at Baxter in a way that is pretty straightforward. Some stuff we expect from people to accomplish at a certain level. Understanding their market is the first one. So when people don't understand their markets or they have been complacent in doing their jobs, it's our responsibility as leaders to identify that, either correct with the personnel that we have or just replace. So that's what we did, and we do that all the time in all businesses. We have significant changes. For instance, we made significant changes in the international business at Baxter, was really under managed, to be honest with you. And we brought some really good people in, and we started seeing the performance going up. Brik had issues with the performance in the hospital business in the U.S., and we just did the same thing. So it's pretty straightforward. No different than it would have been in any other prior jobs, but we take performance very seriously. We take performance as the #1 criteria, only second to ethics and compliance.

    我們看待 Baxter 的執行力,一向相當直接。我們期待大家在某個水準上完成一些事情。第一點是了解他們的市場。所以當有人不了解自己的市場,或在工作上變得自滿時,作為領導者,我們有責任辨識出來:要嘛用現有人員去修正,要嘛就直接更換。這就是我們做的事,而且我們在所有事業中一直都這樣做。我們做了重大的變動。例如,我們在 Baxter 的國際業務做了重大調整;老實說,那塊過去管理不足。我們引進了一些非常優秀的人才,然後開始看到績效上升。Brik 在美國的醫院業務表現上有一些問題,我們也做了同樣的事。所以這很直接。這跟我過去任何工作並沒有不同,但我們非常重視績效。我們把績效視為第一順位的標準,只排在道德與法遵之後。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • As it relates to gross margin, which was a bright spot in the quarter, the lion's share of the improvements relate to cost initiatives and business transformation. As Joe mentioned, we're -- the margin journey that we're on is something that initially was focused primarily on SG&A as that was the fastest area to take out. But now under the leadership of Scott Pleau, we've been able to make changes to our operation network, to facilities, to optimizing within facilities. So probably 75% of our margin improvement year-over-year relates to some of these cost initiatives. And perhaps 25% or so relates to mix and operational growth that took place in the quarter. So on balance, as we look from 2018 to 2023, you can expect to see more progress on driving cost out with a lot of that coming from the gross margin line in the coming years.

    就毛利率而言,本季毛利率是一個亮點,改善的大部分主要來自成本措施與業務轉型。如 Joe 所提到的,我們——目前所走的毛利率改善旅程,起初主要聚焦在 SG&A,因為那是最快能削減的領域。但現在在 Scott Pleau 的領導下,我們已能對營運網路、設施,以及設施內部的最佳化進行調整。因此,我們年對年毛利率改善中,約 75% 來自這些成本措施。而約 25% 左右則來自本季發生的產品組合與營運成長。整體而言,當我們從 2018 年看到 2023 年,您可以預期未來幾年在推動降本方面會有更多進展,其中相當一部分將來自毛利率這一行。

  • Operator

    Operator

  • And our final question comes from the line of Joanne Wuensch of BMO Capital Markets.

    我們最後一個問題來自 BMO Capital Markets 的 Joanne Wuensch。

  • Joanne Karen Wuensch - MD & Research Analyst

    Joanne Karen Wuensch - MD & Research Analyst

  • There are a number of new products that you're launching right now in the second half that should benefit you in 2019, Spectrum IQ, Evo IQ, PRISMAFLEX, PrisMAX. Can you give us a brief update on how those products are rolling out the door? And how we should think about them ramping into next year to possibly offset some of the continued nutritionals and Medication Delivery recovery?

    你們目前在下半年推出多項新產品,應可在 2019 年帶來助益,包括 Spectrum IQ、Evo IQ、PRISMAFLEX、PrisMAX。能否請你們簡要更新一下這些產品的推出進度如何?以及我們應如何看待它們在明年放量成長,可能用以抵消部分持續的營養品與藥物輸注(Medication Delivery)復甦影響?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Yes. Joanne, clearly, we are looking into '19 to be a year that we're going to have growth. The question that we're going to tell you how much growth it's going to be is going to be a conversation in January. Those products will contribute, and we're counting on them to help because as you see some of this change that Brik just mentioned in nutrition is several quarters in the making to recoup that kind of a sales volume. So those new products will be key. We're counting on PrisMAX. I think dex -- that is one that we are very excited. Once we launched dex, it's actually doing very well. We have 4 new molecules launching next year as well. So we -- one thing we have proven is the ability to really ramp up quickly to big sales on those molecules. If I'm not mistaken dexmed will -- peak sales will go into '19. We'll get into '19 pretty quickly. So we need those products. We're counting on KAGUYA next year to be a driver in Japan because the profitability -- not as much as sales growth as much as the profitability. That product has shown that the patient in Japan are highly profitable in terms of our reimbursement. So we are counting on those products without a doubt. And for me, and this is the message that I give to Brik, to Cristiano who runs Europe, Middle East and Africa and Andy Frye. It's all about executing on those new products. They have the message. They know what needs to be done, and we're counting on them. Thank you.

    是的。Joanne,很明顯地,我們把 2019 年視為將會成長的一年。至於我們要告訴你成長幅度會是多少,會是在一月的討論。這些產品會有所貢獻,我們也仰賴它們提供協助,因為如你所見,Brik 剛提到的營養品變化,需要好幾個季度才能收回那樣的銷售量。因此,這些新產品將是關鍵。我們寄望於 PrisMAX。我想 dex——那是一個我們非常興奮的產品。我們一推出 dex,實際上表現就非常好。我們明年也將推出 4 個新分子。因此,我們——有一件事我們已證明,就是我們確實有能力把這些分子快速放量,做到很大的銷售。如果我沒記錯,dexmed——其銷售高峰會落在 2019 年。我們會很快進入 2019 年。所以我們需要這些產品。我們也指望明年的 KAGUYA 成為日本的驅動因素,因為它帶動的是獲利能力——與其說是銷售成長,不如說是獲利能力。該產品已顯示,在日本就我們的給付(reimbursement)而言,病患的獲利性非常高。因此,毫無疑問,我們仰賴這些產品。對我而言,而這也是我傳達給 Brik、負責歐洲、中東與非洲的 Cristiano,以及 Andy Frye 的訊息。重點就在於把這些新產品執行到位。他們已收到訊息。他們知道需要做什麼,我們也仰賴他們。謝謝。

  • Joanne Karen Wuensch - MD & Research Analyst

    Joanne Karen Wuensch - MD & Research Analyst

  • And as my follow-up question, you mentioned that you're a little bit more revitalized on the M&A focus, and you gave a great answer earlier to what you're looking for in terms of size. But is there anything in particular that has made you revitalized? Is it the business as we're seeing it today? Or is it just opportunity or something else?

    作為我的追問,你提到你們在併購(M&A)重點上變得更有動能,你先前也很清楚地回答了你們在規模方面的考量。但是否有任何特別的因素讓你們重新振作、加大併購動能?是因為我們今天所看到的業務狀況嗎?還是只是機會出現,或其他原因?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • If you think about the transformation, Joanne, I put that in 3 different phases, and some of them are all in parallel. But the M&A was the -- and the portfolio revamping and transformation of the portfolio is one that had to come after 2 things that we had to do. We needed to put the house in order in terms of organizational structure, finance, balance sheet and culture. Once we get those things done, and we have our own organic programs, now we have a team that is working diligently on finding opportunities for us to tag along. So if we don't have those things in place, we couldn't do the other. We couldn't come up 6 months into this job and say we're going to buy this company and that company. We didn't have the balance sheet. Now we do. Not only that, we have the strategy, and we have competent leaders, for the most part, that we're making sure that we can execute on this. So as we make adjustments to our organization, I have to say that the people and employees of Baxter have done a significant amount of heavy lifting due to so many headwinds that we had with this hurricane, anticipated and unanticipated, because some of this stuff caught us by surprise not because we didn't prepare but because the long-lasting effect. But the people of Baxter has worked -- have worked relentlessly and get this done. Now it's time for us to really get the M&A going as these things are starting to get behind us.

    Joanne,如果你思考這次轉型,我把它分成 3 個不同階段,其中有些是並行進行的。但併購——以及投資組合的重整與轉型——必須在我們完成兩件事之後才能進行。我們需要先把內部整頓好,包括組織架構、財務、資產負債表與文化。當我們把這些事情做好,並且有我們自身的有機成長計畫之後,現在我們有一個團隊正努力不懈地為我們尋找可切入的機會。所以如果沒有這些基礎,我們就無法做其他事情。我們不可能在上任 6 個月就說我們要買這家公司、那家公司。當時我們沒有那樣的資產負債表。現在我們有了。不僅如此,我們也有策略,而且大多數情況下,我們有稱職的領導者,並確保我們能把這些事情執行到位。因此,當我們對組織做調整時,我必須說,Baxter 的同仁與員工在面對這場颶風帶來的眾多逆風時,做了大量艱鉅的工作——無論是可預期或不可預期的,因為其中一些事情讓我們措手不及,不是因為我們沒有準備,而是因為其影響持續很久。但 Baxter 的同仁一直——一直不懈地努力把這些事情完成。現在,隨著這些事情開始逐步過去,是我們真正推動併購加速的時候了。

  • Operator

    Operator

  • And that was our question and answer session for today. Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating. Everyone, have a great day.

    以上就是我們今天的問答環節。各位女士、先生,Baxter International 今天的電話會議到此結束。感謝各位參與。祝各位有美好的一天。